

Instructions For Use
RA0233-C.5-IFU-RUC

Revision: 1


Rev. Date: Nov. 14, 2014

Page 1 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

MyoD1 (Rhabdomyosarcoma Marker); Clone 5.8A & MYD712 (Concentrate)

Availability/Contents:	<u>ltem #</u> RA0233-C.5	<u>Volume</u> 0.5 ml		
Description:				
Species: Immunogen:	Mouse Recombinant mouse MyoD1 protein (5.8A); Recombinant human MyoD1 protein (MYD712)			
Clone:	5.8A & MYD712			
Isotype: Entrez Gene ID:	IgG1, kappa (5.8A); IgG1, kappa (MYD712) 4654 (Human); 17927 (Mouse)			
Hu Chromosome Loc.:	11p15.1			
Synonyms:	bHLHc1, Class C basic helix-loop-helix protein 1, Myoblast determination protein 1, Myogenic differentiation 1, Myogenic factor 3 (Myf-3), Myogenin D1, PUM			
Mol. Weight of Antigen:	45kDa			
Format:	200µg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide.			
Specificity:	Recognizes a phosphor-protein of 45kDa, identified as MyoD1. It does not cross react with myogenin, Myf5, or Myf6. This antibody to MyoD1 labels the nuclei of myoblasts in developing muscle tissues.			
Background:	MyoD1 is not detected in normal adult tissue, but is highly expressed in the tumor cell nuclei of rhabdomyosarcomas. Occasionally, nuclear expression of MyoD1 is seen in ectomesenchymoma and a subset of Wilm's tumors. Weak cytoplasmic staining is observed in several non-muscle tissues, including glandular epithelium and also in rhabdomyosarcomas, neuroblastomas, Ewing's sarcomas, and alveolar soft part sarcomas.			
Species Reactivity:	Human, Mouse, Rat, and Chicken. Others not known.			
Positive Control:	Rhabdomyosarcoma			
Cellular Localization:	Nuclear. Only nuclear staining should be considered as evidence of skeletal muscle differentiation.			
Titer/ Working Dilution:	Immunohistochemistry (F Flow Cytometry: Immunofluorescence: Western Blotting: Immunoprecipitation:	rozen and Formalin-fixed): 0.5-1 μg/ml 0.5-1 μg/million cells 0.5-1 μg/ml 0.25-0.5 μg/ml 0.5-1 μg/500μg protein lysate		
Microbiological State:	This product is not sterile.			







EC REPEmergoEurope (31)(0) 70 345-8570Molsnstraat 152513 BH Hague, The Netherlands

Doc: IFU-Template2-8rev2



Instructions For Use RA0233-C.5-IFU-RUO


Rev. Date: Nov. 14, 2014

Revision: 1 Page 2 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

Uses/Limitations:

Not to be taken internally. For Research Use Only. This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded tissue sections, to be viewed by light microscopy. Do not use if reagent becomes cloudy. Do not use past expiration date. Non-Sterile.



Formalin-fixed, paraffin-embedded rhabdomyosarcoma stained with MyoD1; Clone 5.8A & MYD712.

Procedure:

- 1. **Tissue Section Pretreatment (Highly Recommended):** Staining of formalin fixed, paraffin embedded tissue sections is significantly enhanced by pretreatment with EDTA Buffer (10X) HIER Solution (pH 8.0) (ScyTek catalog# ETA).
- Primary Antibody Incubation Time: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.
- 3. **Visualization:** For maximum staining intensity we recommend the "UltraTek HRP Anti-Polyvalent Lab Pack" (ScyTek catalog# UHP125, see IFU for instructions) combined with the "DAB Chromogen/Substrate Bulk Pack (High Contrast)" (ScyTek catalog# ACV500, see IFU for instructions).

 Precautions:
 Contains Sodium Azide as a preservative (0.09% w/v).

 Do not pipette by mouth.
 Avoid contact of reagents and specimens with skin and mucous membranes.

 Avoid microbial contamination of reagents or increased nonspecific staining may occur.
 This product contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200, OSHA Hazardous Communication Standard and EC Directive 91/155/EC.

References:

1. Thulasi R et. al. Cell Growth and Differentiation, 1996, 7(4):531-41.

Ordering Information and Current Pricing at www.scytek.com

- 2. Wesche WA et. al. American Journal of Surgical Pathology, 1995, 19(3):261-9.
- 3. Parham DM et. al. Acta Neuropathologica, 1994, 87:605-11.

Warranty:

No products or "Instructions For Use (IFU)" are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our IFU or website. Our warranty is limited to the actual price paid for the product. ScyTek Laboratories, Inc. is not liable for any property damage, personal injury, time or effort or economic loss caused by our products. Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining can cause inconsistent results. Variations in fixation and embedding or the inherent nature of the tissue specimen may cause variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and endogenous biotin may cause non-specific staining depending on detection system used.

8° C Storage: 2° C



ScyTek Laboratories, Inc. 205 South 600 West Logan, UT 84321 U.S.A.



EC REPEmergoEurope (31)(0) 70 345-8570Molsnstraat 152513 BH Hague, The Netherlands